Eight-ounce scanner assesses heart function.
The U.S. Food & Drug Administration (FDA) has awarded 510(k) clearance to the hand-held ultrasound platform Kosmos, produced by the developer EchoNous.
By using machine learning, Kosmos can imitate humans’ learning and decision-making processes, according to the company. The 8-oz ultrasound tool has embedded and synchronized ECG and digital auscultation. Currently, the tool measures systolic heart function.
In addition, EchoNous has side-stepped the need for cloud connectivity with the Kosmos Bridge, a tablet that accompanies the platform. All artificial intelligence functions run on the tablet, ensuring there are no service failures during scans, EchoNous officials said. It is also designed to connect with a health system's IT system without a need for internet connectivity.
According to EchoNous officials, the Kosmos platform has been tested with more than 300 patients in acute care settings in the United States, Canada, Europe, and Japan. It will be available in the U.S. market for less than $10,000.
As a next step, company officials said, EchoNous plans to file for FDA clearance for a trio of algorithms that will allow users use machine learning algorithms to grade image quality, guide their technique, and label heart anatomy.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
Improving Adherence to Best Practices for Incidental Abdominal Aortic Aneurysms on CT and MRI
November 5th 2024In recent interviews, Eric Rohren, M.D., and Krishna Nallamshetty, M.D., discuss the potential of abdominal aortic aneurysms (AAAs) to progress into life-threatening consequences and an emerging AI-powered tool that may bolster adherence to best practice recommendations in radiology reporting of incidental AAA findings on CT and MRI.